The average one-year price target for ProMIS Neurosciences (NasdaqCM:PMN) has been revised to $35.06 / share. This is a decrease of 57.76% from the prior estimate of $83.00 dated February 21, 2026.

View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Studies have shown that PMN from adults and neonates exhibit heterogeneity of function and 31D8 MAb binding. The heterogenity of 31D8 binding correlates with PMN motile heterogeneity. MOI MAb binds to ...

ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), ...

As highlighted above, PMN are a vital component of the innate immune system and comprise a critical component of the army of first responsers to sites of inflammation. 1, 2 Although it is clear that ...

BIRMINGHAM, Ala. - University of Alabama at Birmingham researchers have found a novel, previously unreported pathogenic entity that is a fundamental link between chronic inflammation and tissue ...